Warp Sciences emerges from stealth with $215M for AI-driven drug discovery infrastructure

By ASR Newsdesk · 28 Oct 2026, 18:00 UTC

Warp Sciences has launched from stealth, securing $215 million in funding to develop U.S.-based chemistry infrastructure for biotech and pharmaceutical companies. The startup aims to accelerate drug discovery by integrating chemists, robotics, and AI to create and test molecules. By generating experimental data at scale, Warp Sciences intends to train more capable AI models, leading to faster hypothesis testing and improved lab automation. The company emphasizes providing sovereign biotechnology solutions, offering a U.S.-based alternative for chemistry services with a focus on speed, quality, and intellectual property protection.